Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423195 · ClinicalTrials.gov registry record
Impact of Cannabis Use During Third Molar Surgery
A clinical trial of Cannabis Use and Sedation and Analgesia, sponsored by University of Michigan.
- Recruiting
- Registry status
- 242
- Enrollment target
- 1
- Study location
NCT07423195: Recruiting study of Cannabis Use and Sedation and Analgesia, sponsored by University of Michigan.
NCT07423195 is a study of Cannabis Use and Sedation and Analgesia that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 242 participants, below the 274-participant average among 44 other Cannabis Use trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07423195, a study of Cannabis Use and Sedation and Analgesia, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 242 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for people scheduled to have their wisdom teeth (third molars) removed and are going to receive drug through an IV to put them to sleep. The researchers are studying two groups: one group of people who report using recreational marijuana/THC/cannabis and another group who report not using it. They want to look at how both users and non-users do during the tooth removal.
Primary Outcome
Amount (mg) of midazolam administered during third molar removal surgeries utilizing deep (IV) sedation in patients who are cannabis users versus cannabis non-users. The amount of these medications is registered by the timing of each administration, as well as the total amount of each medication given throughout the procedure.
Conditions Studied
Study Locations (1)
Michigan
- University of Michigan School of Dentistry/ Oral and Maxillofacial Surgery - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2030-01 |
What NCT07423195 shows while recruiting
NCT07423195 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 44 other Cannabis Use trials with a reported enrollment target (12% lower).
The record links to 4 conditions, with Cannabis Use appearing as the primary indexed condition, and to 0 interventions.
NCT07423195 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07423195 about?
NCT07423195 is a clinical study titled "Impact of Cannabis Use During Third Molar Surgery". This study is for people scheduled to have their wisdom teeth (third molars) removed and are going to receive drug through an IV to put them to sleep. The researchers are studying two groups: one group of people who report using recreational marijuana/THC/cannabis and another group who report not u...
What is the current status of trial NCT07423195?
This trial is currently recruiting. The enrollment target is 242 participants. The study started on 2026-01-14. Estimated completion is 2030-01.
What conditions does trial NCT07423195 study?
This clinical trial studies the following conditions: Cannabis Use, Sedation and Analgesia, Marijuana Usage, Wisdom Tooth.
Who is sponsoring clinical trial NCT07423195?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07423195 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07423195's enrollment target sits among peer trials
242 9th of 44 higher than 36 of 44 other Cannabis Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use
RECRUITING · NA
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
SV2A in Older Adults
RECRUITING · Phase 1
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)
RECRUITING · NA
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI